Results showed non-inferiority for linagliptin vs glimepiride in meeting its primary endpoint of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke.
In people with uncontrolled type 2 diabetes, dapagliflozin was superior to sitagliptin in reducing 3 major cardiovascular risk factors.
Both pediatric and adult patients with type 1 diabetes had favorable outcomes for glycemic control with use of the Omnipod® Insulin Management System.
The International Consensus on Time-in-Range proposed evidence-based clinical targets for routine continuous glucose monitoring.
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
Linagliptin is safe for patients with type 2 diabetes and cardiorenal disease.
Oral semaglutide had positive effects on HbA1c reduction and weight loss when added to insulin.
Dasiglucagon was found to be an effective and safe treatment option for severe hypoglycemia in type 1 diabetes.
CERT predicted cardiovascular mortality in patients with known cardiovascular risk who had type 2 diabetes, as well as in patients without diabetes.
Patients who attended complication screenings paid more visits to diabetes clinics within the first 2 years after diagnosis, had higher median lifetime HbA1c, and had less socioeconomic disadvantage.
Closed-loop insulin delivery may mitigate potential changes in glycemic control throughout the menstrual cycle.
Combination treatment with a SGLT2 inhibitor and exenatide may protect renal function and reduce all-cause mortality risk in patients with type 2 diabetes.
Ultra-rapid insulin lispro in a basal-bolus regimen demonstrated superiority in terms of postprandial glucose control compared with insulin lispro.
Treatment with empagliflozin may reduce liver fat content and increase serum adiponectin in patients with well-controlled type 2 diabetes.
Treatment with dapagliflozin may limit the rise in urinary albumin excretion in patients with type 2 diabetes.